New phase I trial methodology

Sridhar Mani, M. J. Ratain

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Phase I trial design is constantly evolving to adapt to deficiencies in traditional methods and to accommodate newer rationally designed agents. This article discusses some of the important aspects of the design of phase I studies with particular reference to identifying new methods of safer but rapid dose escalation and reproducible end points such as maximum tolerated dose and recommended phase II dose. Given the explosion of rationally designed drugs capable of pathway specific inhibition, we also discuss potential strategies in designing trials with these agents. It is hoped that future strategies incorporate the existing methodologies with newer dose titration examples to complete phase I trials in a rapid and timely fashion.

Original languageEnglish (US)
Pages (from-to)253-261
Number of pages9
JournalSeminars in Oncology
Volume24
Issue number2
StatePublished - 1997
Externally publishedYes

Fingerprint

Maximum Tolerated Dose
Explosions
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology

Cite this

Mani, S., & Ratain, M. J. (1997). New phase I trial methodology. Seminars in Oncology, 24(2), 253-261.

New phase I trial methodology. / Mani, Sridhar; Ratain, M. J.

In: Seminars in Oncology, Vol. 24, No. 2, 1997, p. 253-261.

Research output: Contribution to journalArticle

Mani, S & Ratain, MJ 1997, 'New phase I trial methodology', Seminars in Oncology, vol. 24, no. 2, pp. 253-261.
Mani, Sridhar ; Ratain, M. J. / New phase I trial methodology. In: Seminars in Oncology. 1997 ; Vol. 24, No. 2. pp. 253-261.
@article{901bf3e40a6a4c58bd08cf5c27002ab0,
title = "New phase I trial methodology",
abstract = "Phase I trial design is constantly evolving to adapt to deficiencies in traditional methods and to accommodate newer rationally designed agents. This article discusses some of the important aspects of the design of phase I studies with particular reference to identifying new methods of safer but rapid dose escalation and reproducible end points such as maximum tolerated dose and recommended phase II dose. Given the explosion of rationally designed drugs capable of pathway specific inhibition, we also discuss potential strategies in designing trials with these agents. It is hoped that future strategies incorporate the existing methodologies with newer dose titration examples to complete phase I trials in a rapid and timely fashion.",
author = "Sridhar Mani and Ratain, {M. J.}",
year = "1997",
language = "English (US)",
volume = "24",
pages = "253--261",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - New phase I trial methodology

AU - Mani, Sridhar

AU - Ratain, M. J.

PY - 1997

Y1 - 1997

N2 - Phase I trial design is constantly evolving to adapt to deficiencies in traditional methods and to accommodate newer rationally designed agents. This article discusses some of the important aspects of the design of phase I studies with particular reference to identifying new methods of safer but rapid dose escalation and reproducible end points such as maximum tolerated dose and recommended phase II dose. Given the explosion of rationally designed drugs capable of pathway specific inhibition, we also discuss potential strategies in designing trials with these agents. It is hoped that future strategies incorporate the existing methodologies with newer dose titration examples to complete phase I trials in a rapid and timely fashion.

AB - Phase I trial design is constantly evolving to adapt to deficiencies in traditional methods and to accommodate newer rationally designed agents. This article discusses some of the important aspects of the design of phase I studies with particular reference to identifying new methods of safer but rapid dose escalation and reproducible end points such as maximum tolerated dose and recommended phase II dose. Given the explosion of rationally designed drugs capable of pathway specific inhibition, we also discuss potential strategies in designing trials with these agents. It is hoped that future strategies incorporate the existing methodologies with newer dose titration examples to complete phase I trials in a rapid and timely fashion.

UR - http://www.scopus.com/inward/record.url?scp=0030968315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030968315&partnerID=8YFLogxK

M3 - Article

VL - 24

SP - 253

EP - 261

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 2

ER -